ArticleBrain and behavior2025
TLR1-Regulated Ferroptosis Gene Decreases the Occurrence of Restless Legs Syndrome.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TLR1-Regulated Ferroptosis Gene Decreases the Occurrence of Restless Legs Syndrome.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRestless legs syndrome (RLS) is a sensory motor neuropathy that is frequently encountered. Transcriptome analysis has revealed the role of ferroptosis in the pathogenesis of RLS. However, the role of ferroptosis in RLS and the upstream regulatory molecules governing ferroptosis remain unknown.
methodsThis study aims to explore the causal relationship and mechanisms between ferroptosis genes, upstream genes, and RLS using Mendelian Randomization (MR). This study employed two-sample MR analysis and mediation analysis, utilizing RLS GWAS data from the Finngen database, ferroptosis genes data from the decode database, and upstream genes data from the the UK Biobank Pharma Proteomics Project. A two-sample MR analysis was used to evaluate the causal relationship between the ferroptosis genes and RLS. Then, mediation analysis was conducted to explore the mediating effect of upstream genes on the relationship between expression of ferroptosis genes and RLS.
resultsOur study found a significant positive correlation between high expression of the FURIN gene and a reduced risk of RLS. Further exploration of upstream genes regulating ferroptosis genes revealed that these genes indirectly influence the occurrence of RLS by regulating the expression of the FURIN gene. Mediator effect analysis showed that TLR1 indirectly reduces the occurrence of RLS by regulating the expression of the FURIN gene, with the mediator effect of FURIN gene expression accounting for 17.9% of the total effect. Sensitivity analysis supported our findings, indicating high statistical robustness.
conclusionThis study highlights the role of TLR1 in regulating FURIN during the progression of RLS, suggesting the potential clinical application of FURIN as a therapeutic target for the early diagnosis and treatment of RLS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.